Phase III
ARGX-113-2011: A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
- Study HIC#:2000035976
- Last Updated:03/24/2026
- Age18 years and older
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
Sarah Hall
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
